Dec. 21 at 6:32 PM
Updated schedule of what's happened to the share prices of all 61 new commercial-stage oncology focused bios since 1/1/13 (v. share prices @ FDA approval).
The biggest take-aways?
1. Only 7 of the 32 still independent trade at higher share prices today. That's not a typo...only 7 of 32.
2. 17 were sold at meaningful gains for shareholders. 15 of these 17 were sold within 2 years of FDA approval.
3. 9 of the 61 were sold at big losses. 8 of the 9 waited for over 2 years to sell.
4. 3 of the 61 went bankrupt
5. Had you purchased
$1,000 worth of stock at the time of approval in all 61 bios, your
$61,000 investment would be worth
$60,103 today.
Remember, 95 to 98% of new cancer drugs in Phase 1 trials are never approved. This is why 95% of clinical-stage bios fail & probably why those that wait to sell result in losses for shareholders.
$NUVB is the best performing stock in this peer group to date.
For
$IOVA 2 years comes 2/16/26,
$DAWN 4/23/26 & SNDX 8/14/26
Will
$IMCR &
$URGN be outliers?
